Hepatitis C

Hepatitis C treatment given orphan medicinal product designation in Europe

Published in Hepatitis Weekly, July 18th, 2005

Nabi Biopharmaceuticals (NABI) announced that, following the favorable opinion of the European Medicines Agency or EMEA (adopted by the Committee of Orphan Medicinal Products), the European Commission has granted orphan medicinal product (OMP) designation to Civacir [Hepatitis C Immune Globulin (Human)].

Civacir is Nabi Biopharmaceuticals' product candidate for the prevention of recurrent hepatitis C virus-induced liver disease in liver transplant recipients. The OMP designation will result in reduced marketing authorization application (MAA) fees, free access to scientific advice from the EMEA and other potential research and development incentives.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry